Show simple item record

dc.contributor.authorMitchell, Claire L
dc.contributor.authorO'Connor, James P B
dc.contributor.authorRoberts, C
dc.contributor.authorWatson, Y
dc.contributor.authorJackson, A
dc.contributor.authorCheung, S
dc.contributor.authorEvans, J
dc.contributor.authorSpicer, J
dc.contributor.authorHarris, A
dc.contributor.authorKelly, C
dc.contributor.authorRudman, S
dc.contributor.authorMiddleton, M
dc.contributor.authorFielding, A
dc.contributor.authorTessier, J
dc.contributor.authorYoung, H
dc.contributor.authorParker, G J M
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2012-05-28T11:55:20Z
dc.date.available2012-05-28T11:55:20Z
dc.date.issued2011-09
dc.identifier.citationA two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. 2011, 68 (3):631-41 Cancer Chemother Pharmacolen_GB
dc.identifier.issn1432-0843
dc.identifier.pmid21120480
dc.identifier.doi10.1007/s00280-010-1534-3
dc.identifier.urihttp://hdl.handle.net/10541/226214
dc.description.abstractCediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer chemotherapy and pharmacologyen_GB
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshArea Under Curve
dc.subject.meshCross-Over Studies
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshElectrocardiography
dc.subject.meshFasting
dc.subject.meshFemale
dc.subject.meshFood-Drug Interactions
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshQuinazolines
dc.subject.meshTomography, X-Ray Computed
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleA two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Claire.Mitchell@christie.nhs.uken_GB
dc.identifier.journalCancer Chemotherapy and Pharmacologyen_GB
refterms.dateFOA2020-04-27T12:58:29Z
html.description.abstractCediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers.


Files in this item

Thumbnail
Name:
234011.pdf
Size:
543.3Kb
Format:
PDF
Description:
CORE by link

This item appears in the following Collection(s)

Show simple item record